These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...

EST Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...

Struggling genetic testing 23andMe is looking for a buyer for the virtual care business it acquired in 2021, Business Insider ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

Successfully scaling gen AI requires clear, high-value use cases, technological flexibility and an adaptive workforce.

A BofA analyst finds a lot to like in Disney’s media and entertainment categories. The company will report earnings on Feb. 5 ...

Businessman Frank McCourt is "open-minded" to keeping TikTok's existing investors, including the founder, involved after any ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...